Cancer Family
Carcinoma
CI-CAN-00000114Explore in graph →
7,369 active trials118 approved drugs1,149 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000114Explore in graph →
Clinical trials
25,729 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (3,405)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04511793 | Hepatic Artery Infusion (HAI) Program at Duke University | withdrawn | N/A | 0 | Michael Lidsky, M.D.OTHER | 0 | Jul 19, 2021 | clinicaltrials |
| NCT04093401 | The VIDYA Study-designed to Determine if Patients With a History of Basal Cell Carcinoma Are More Inclined to Return for Follow-up if Their Risk of a Subsequent Basal Cell Carcinoma is Quantitated. | withdrawn | N/A | 0 | University of Wisconsin, MadisonOTHER | 0 | Jul 14, 2021 | clinicaltrials |
| NCT04067102 | Nab-paclitaxel Based Regimens VS Paclitaxel Based Regimens in Neoadjuvant Treatment for TNBC | withdrawn | N/A | 0 | Hebei Medical University Fourth HospitalOTHER | 1 | Jul 9, 2021 | clinicaltrials |
| NCT04947371 | Adjuvant Therapy With Anlotinib for HCC | withdrawn | Phase 2 | 0 | Shanghai Zhongshan HospitalOTHER | 1 | Jul 1, 2021 | clinicaltrials |
| NCT04479904 | A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma | withdrawn | Phase 2 | 0 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 0 | Jun 22, 2021 | clinicaltrials |
| NCT04270929 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma(PANC-001) | withdrawn | Phase 1 | 0 | Roger Williams Medical CenterOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT03536182 | Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer(CIPHER) | withdrawn | Phase 3 | 0 | University of Texas Southwestern Medical CenterOTHER | 2 | May 26, 2021 | clinicaltrials |
| NCT04498520 | Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer | withdrawn | Phase 1 | 0 | Pamela MunsterOTHER | 0 | May 18, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT03673735 | Maintenance Immune Check-point Inhibitor Following Post-operative Chemo-radiation in Subjects With HPV-negative HNSCC(ADHERE) | withdrawn | Phase 3 | 0 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 0 | May 10, 2021 | clinicaltrials |
| NCT00380666 | The Utility of PET/CT in the Planning of Stereotactic Body Radiotherapy for Non-small Cell Lung Cancer | withdrawn | N/A | 0 | University of AarhusOTHER | 0 | May 6, 2021 | clinicaltrials |
| NCT03390738 | Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous Chemotherapy | withdrawn | Phase 2 | 0 | The University of Hong KongOTHER | 0 | May 3, 2021 | clinicaltrials |
| NCT00492947 | Dendritic Cell Vaccine for Head and Neck Cancer(Dendritic) | withdrawn | Phase 1 | 0 | University of Maryland, BaltimoreOTHER | 1 | Apr 30, 2021 | clinicaltrials |
| NCT02038699 | A First-in-man Phase I/II Study of Oral ONC201 in Patients With Advanced Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Jazz PharmaceuticalsINDUSTRY | 1 | Apr 30, 2021 | clinicaltrials |
| NCT03452553 | Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin | withdrawn | N/A | 0 | Boston Scientific CorporationINDUSTRY | 0 | Apr 21, 2021 | clinicaltrials |
| NCT03902379 | Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer | withdrawn | N/A | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT03773744 | MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma(Pelican) | withdrawn | Phase 1 | 0 | Turnstone Biologics, Corp.INDUSTRY | 0 | Apr 6, 2021 | clinicaltrials |
| NCT03189186 | Phase-I Trial of Pembrolizumab and Percutaneous Cryoablation Combination Followed by Nephron-Sparing Surgery or Cytoreductive Nephrectomy in Locally Advanced and Metastatic Renal Cell Carcinomas | withdrawn | Phase 1 | 0 | University of California, IrvineOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of Southern CaliforniaOTHER | 1 | Apr 5, 2021 | clinicaltrials |
| NCT00892255 | Microwave Ablation of Resectable Liver Tumors | withdrawn | — | 0 | St. Joseph Hospital of OrangeOTHER | 1 | Apr 2, 2021 | clinicaltrials |
| NCT04069442 | cDC1 Prognostic and Predictive Role in Non-Small-Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors(LUNG-PREDICT) | withdrawn | — | 0 | University Hospital, GrenobleOTHER | 1 | Apr 1, 2021 | clinicaltrials |
| NCT01237171 | A Study of Cesium-131 Brachytherapy Following Sub-Lobar Resection for Early Stage Non Small Cell Lung Cancer | withdrawn | — | 0 | IsoRay Medical, Inc.INDUSTRY | 1 | Mar 30, 2021 | clinicaltrials |
| NCT04404647 | Irreversible Electroporation of Unresectable Liver Tumors | withdrawn | N/A | 0 | Ole Thorlacius-Ussing, MD, DMSc, Professor of SurgeryOTHER | 1 | Mar 26, 2021 | clinicaltrials |
| NCT03649035 | Eus-guided Cryothermal Ablation in Stage III Pancreatic Adenocarcinoma | withdrawn | Phase 3 | 0 | Istituto Clinico HumanitasOTHER | 1 | Mar 19, 2021 | clinicaltrials |
| NCT02272699 | Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma | withdrawn | Phase 2 / Phase 3 | 0 | Peking UniversityOTHER | 1 | Mar 18, 2021 | clinicaltrials |
| NCT03437915 | BrUOG 351: PRE-OPERATIVE APBI USING NIBB(351) | withdrawn | N/A | 0 | Jaroslaw HepelOTHER | 0 | Mar 9, 2021 | clinicaltrials |
| NCT04543916 | Venetoclax and Irinotecan in Relapsed/Refractory SCLC | withdrawn | Phase 1 / Phase 2 | 0 | Virginia Commonwealth UniversityOTHER | 0 | Mar 3, 2021 | clinicaltrials |
| NCT04526080 | Intrabucally Administered Electromagnetic Fields Versus Placebo as Third-line Therapy For Patients With Advanced Hepatocellular Carcinoma(TheraBionics) | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 1 | Feb 26, 2021 | clinicaltrials |
| NCT01707056 | The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma | withdrawn | N/A | 0 | Medstar Health Research InstituteOTHER | 1 | Feb 17, 2021 | clinicaltrials |
| NCT02129322 | Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | withdrawn | Phase 2 | 0 | Zhejiang UniversityOTHER | 1 | Feb 15, 2021 | clinicaltrials |
| NCT04398927 | Systemic Chemotherapy Plus PD-1 for Metastasis ICC | withdrawn | Phase 2 | 0 | Sun Yat-sen UniversityOTHER | 1 | Feb 4, 2021 | clinicaltrials |
| NCT02867722 | Daylight Photodynamic Therapy for the Treatment of Actinic Keratoses in the Northeast United States(DaylightPDT) | withdrawn | N/A | 0 | Brigham and Women's HospitalOTHER | 0 | Feb 1, 2021 | clinicaltrials |
| NCT00247936 | Combined Thoracoscopic and Laparoscopic Esophagectomy vs. Hand-assisted Transhiatal Esophagectomy: A Prospective Trial. | withdrawn | N/A | 0 | University of California, IrvineOTHER | 0 | Jan 26, 2021 | clinicaltrials |
| NCT03901378 | Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | withdrawn | Phase 2 | 0 | Ochsner Health SystemOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT04585932 | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT04205071 | Lorcaserin in Treating Chemotherapy-Induced Peripheral Neuropathy in Patients With Stage I-IV Gastrointestinal or Breast Cancer | withdrawn | Phase 1 | 0 | Ohio State University Comprehensive Cancer CenterOTHER | 0 | Jan 19, 2021 | clinicaltrials |
| NCT03760614 | A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jan 15, 2021 | clinicaltrials |
| NCT03563352 | Nutritional Preferences and Product Accessibility in Oral Nutritional Supplements in Participants With Breast, Colorectal, Upper Gastrointestinal, or Prostate Cancer | withdrawn | — | 0 | University of Southern CaliforniaOTHER | 1 | Dec 14, 2020 | clinicaltrials |
| NCT03257332 | Determining Early Development of Faecal Incontinence and Anorectal Muscle Function After Surgery for Rectal Cancer.(EDFI-Cohort) | withdrawn | — | 0 | Slagelse HospitalOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT03295695 | PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient | withdrawn | Early Phase 1 | 0 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2020 | clinicaltrials |
| NCT04460729 | A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases | withdrawn | Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 3, 2020 | clinicaltrials |
| NCT03040453 | Immunological Response After Ablative Therapy in the Liver(IRAL) | withdrawn | N/A | 0 | Karolinska InstitutetOTHER | 1 | Nov 30, 2020 | clinicaltrials |
| NCT03361319 | Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma(N3) | withdrawn | Phase 1 / Phase 2 | 0 | Royal Marsden NHS Foundation TrustOTHER | 0 | Nov 24, 2020 | clinicaltrials |
| NCT04267913 | Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) | withdrawn | Phase 2 | 0 | SWOG Cancer Research NetworkNETWORK | 0 | Nov 20, 2020 | clinicaltrials |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION(DOMINATION) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Nov 17, 2020 | clinicaltrials |
Data updated 24 days agoSource updated Jul 19, 2021source: clinicaltrials